A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee.

The factors “time on study” and baseline “pain on average” score measured on the BPI scale had a highly significant effect ( P < .001) on the BPI scale “pain on average” score, which means baseline pain severity and time treated with the study drug had an influence on pain on average at endpoint; study joint (hip or knee) had no significant impact on the BPI scale “pain on average” score.

also in 132,142 other papers